Delivery Order SPE2DB20D2104-SPE2DB24FR79E
- Not listed
- This is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $14,794.76 firm-fixed-price contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has a completion date of February 13, 2024. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The award, valued at $7,148.93, is a firm fixed-price delivery order with a completion date of June 23, 2022. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies, particularly...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract valued at $6,522.87 to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML and has an ultimate completion date of May 10, 2024. The award is not associated with a set-aside program. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $7,480.06 firm fixed price contract is for the supply of DUPIXENT 200 MG/1.14 ML PEN 1.14ML, a specialty pharmaceutical product, with a completion date of December 1, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $5,760.81 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of April 26, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026....
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $17,380.44 delivery order is for the supply of 4560749784 DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of April 28, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a delivery order contract awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $7,405.52 firm fixed-price contract is for the procurement of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has a completion date of February 8, 2024. There is no set-aside designation, indicating the contract was competitively awarded. Amerisourcebergen Drug Corp is a major pharmaceutical...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $19,628.74, is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The award is a firm fixed-price delivery order with a completion date of January 30, 2024. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a $41,935.36 firm fixed-price delivery order placed by the Defense Logistics Agency (DLA). The contract covers the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a period of performance through February 15, 2024. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $8,799.97 for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The award was made by the Defense Logistics Agency (DLA), a defense agency, on April 5, 2022 with an ultimate completion date of April 6, 2022. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB24FR79EDelivery Order
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The $10,509.49 firm-fixed-price contract has a completion date of December 26, 2023. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that serves as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems. The company holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies. This delivery order is part of that broader IDC vehicle, which enables efficient government procurement of essential medical commodities to support military healthcare programs. The contract award did not utilize any set-aside designation, indicating full and open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 12/22/23 |